ANGLE plc

The decision makers in ANGLE plc are Alexandre Izmailov, Andrew Newland, Brian Howlett, etc. Click to Find ANGLE plc decision makers emails.

The Parsortix® PC1 Clinical System is ANGLE's patented liquid biopsy platform designed to isolate circulating tumor cells (CTCs) from blood samples. It utilizes a unique microfluidic technology that captures CTCs based on their size and deformability, allowing for the separation of rare cells from a complex mixture of blood components. This system is FDA cleared and enables non-invasive cancer diagnostics, providing valuable insights for clinical research and treatment decisions.

ANGLE's liquid biopsy technology, particularly the Parsortix® system, is applicable to various types of cancers, including but not limited to breast, prostate, lung, and colorectal cancers. By isolating CTCs, the system allows for comprehensive molecular analysis, which can aid in early detection, monitoring treatment response, and understanding tumor heterogeneity across different cancer types.

ANGLE provides essential tools and services for clinical research and drug development through its liquid biopsy technology. Researchers can utilize the Parsortix® system to collect and analyze CTCs, enabling them to study cancer biology, assess treatment efficacy, and identify potential biomarkers. This capability supports the development of targeted therapies and personalized medicine approaches, enhancing the overall efficiency of clinical trials.

ANGLE's cell separation technology is beneficial across multiple industries, including oncology, clinical diagnostics, and medical research. It is particularly valuable for hospitals, research institutions, and pharmaceutical companies that require precise isolation of rare cells for cancer diagnostics, biomarker discovery, and therapeutic development. Additionally, the technology can be applied in fetal health monitoring and other areas of medical diagnostics.

Yes, the Parsortix® PC1 Clinical System is designed for routine clinical use and has received FDA clearance for its application in cancer diagnostics. Its user-friendly interface and robust performance make it suitable for integration into clinical workflows, allowing healthcare professionals to easily obtain and analyze CTCs from patient blood samples for diagnostic and monitoring purposes.

To learn more about ANGLE's solutions and services, you can visit their official website at http://www.angleplc.com. The site provides comprehensive information about their liquid biopsy technology, clinical applications, and the various industries they serve. Additionally, you can access resources such as case studies, white papers, and contact details for inquiries regarding collaborations or product demonstrations.